$12 Wednesday, page-39

Timing for next year looks good.

TRS is above my average buy in price, so I'm pretty happy about that at the moment. I was a little concerned when the price dropped to the low $5.00's. Hopefully a good half yearly will give it a lift off.

I'm sure you meant BAL, cause BML looks very high risk.
As for BAL, who knows. It's already gone through the roof, but who knows when it's going to stop.
I originally bought in and sold at $5.19 thinking it had run its course.
I'm now back in at an average of $11.85 with a stop loss at $12.50.
The other one that I thought had run its course was A2M, which I did extremely well out of, but sold out a bit early at $1.00. Just a few days before a profit guidance upgrade.
That's why I'm not that good at picking the top or bottom.

I had a look at your list and SRX has been a star performer. Even after their announcement about their not so good trial results it bounced back to new highs.
As for the others, too risky for me. I've lost too much money over the years and learnt my lesson.
Mind you I've got a sh@#t load of accumulated losses to offset any gains I make for quite some time yet.